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Abstract
Background:  Recent reports have raised concerns that postnatal steroids may cause neuro-
developmental impairment in preterm infants. This systematic review was performed with the
objective of determining whether glucocorticoid therapy, to prevent or treat bronchopulmonary
dysplasia, impairs neuro-developmental outcomes in preterm infants.
Method:  A systematic review of the literature was performed. Medline was searched and articles
retrieved using predefined criteria. Data from randomized controlled trials with adequate neuro-
developmental follow up (to at least one year) were entered into a meta-analysis to determine the
effects of postnatal treatment of preterm infants with glucocorticoids. Cerebral palsy rates, and
neuro-developmental impairment (developmental score more than 2SD below the mean, or
cerebral palsy or blindness) were analyzed. The studies were divided into 2 groups according to
the extent of contamination of the results by treatment of controls with steroids after the initial
study period, those with less than 30% contamination, and those with more than 30%
contamination or size of contamination not reported.
Results:  Postnatal steroid therapy is associated with an increase in cerebral palsy and neuro-
developmental impairment. The studies with less contamination show a greater effect of the
steroids, consistent with a real direct toxic effect of steroids on the developing central nervous
system. The typical relative risk for the development of cerebral palsy derived from studies with
less than 30% contamination is 2.86 (95% CI 1.95, 4.19). The typical relative risk for the
development of neuro-developmental disability among followed up infants from studies with less
than 30% contamination is 1.66 (95% CI 1.26, 2.19). From this subgroup of studies, the number of
premature infants who need to be treated to have one more infant with cerebral palsy (number
needed to harm, NNH) is 7; to have one more infant with neuro-developmental impairment the
NNH is 11.
Conclusions:  Postnatal pharmacologic steroid treatment for prevention or treatment of
bronchopulmonary dysplasia is associated with dramatic increases in neuro-developmental
impairment. As there is no clear evidence in the literature of long term benefit, their use for this
indication should be abandoned.
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The history of Neonatology has been a chequered one.
Huge, well documented, progressive improvements in
neonatal outcomes have been interspersed with multiple
setbacks. These disasters have included: an epidemic of
retinopathy of prematurity due to unregulated adminis-
tration of oxygen [1], followed by an increase in cerebral
palsy rates when oxygen therapy was too severely re-
stricted [2]; the grey baby syndrome from the use of chlo-
ramphenicol when no adequate pharmacokinetic studies
had been performed [3]; a gasping syndrome from the
use of untested bacteriostatic chemicals in flush solu-
tions [4]; and a neurological syndrome due to bathing in-
fants with hexachlorophene and its unexpected
absorption through the skin [5]. All of these disasters
have the common underlying cause of introducing ther-
apies into the care of the most fragile of patients without
adequate investigation of their potential harm. Despite
this history, the postnatal administration of corticoster-
oids for treatment and prevention of chronic lung dis-
ease has become extremely widespread without
adequate analysis of long term adverse effects.
The postnatal use of pharmacological doses of corticos-
teroids came into wide use in neonatal intensive care
nurseries following the illustration of short-term im-
provements in lung mechanics and oxygenation, largely
initially as a result of uncontrolled experimentation (for
one of which publications I was responsible myself [6]).
After many years of further experimentation it has grad-
ually become clear that the only benefit that can be ex-
pected from postnatal steroids is an acute improvement
in gas exchange and lung mechanics [7]. There does not
appear to be any improvement in long-term pulmonary
health, as evidenced by the number of babies going home
on oxygen or the duration of hospitalization, and there
are no adequate long-term pulmonary function studies.
The Cochrane systematic review of "moderately early
steroids to prevent bronchopulmonary dysplasia" [8]
suggests that administration of steroids at 7 to 14 days of
age to ventilator and oxygen dependent infants, the post-
natal age at which the benefits seem to be greatest, ap-
pears to reduce the number of babies who require oxygen
at 36 weeks gestation (i.e. a reduction in the rate of diag-
nosis of BPD). This review also reveals no significant ef-
fect on mortality before discharge, the relative risk of
death is 0.71, with 95% confidence intervals of 0.44 to
1.15. In another systematic review, Doyle and Davis
pointed out that the late mortality in one study was not
included in the Cochrane review, and were unable to
demonstrate an improvement in mortality in any age
group [9]. Specifically the relative risk of mortality
among the studies with steroids commenced at 7 to 14
days was 0.81, (event rate difference was -5%, 95% CI -11,
1.1) and was not statistically significant.
As noted above, the short term improvements in lung
function do not appear to translate into long-term im-
provement in health outcomes. In contrast to the lack of
demonstrated long-term benefit, there have been recent
suggestions that the long-term neurodevelopment of ba-
bies who have received pharmacological doses of ster-
oids may be substantially impaired, with a major
increase in developmental disabilities and movement
disorders [10]. There has been a major delay in the detec-
tion of this effect as most studies have been unable detect
such an effect, even on the rare occasions it has been
looked for [11], because of the frequent use of steroids in
the control groups of randomized studies, ranging up to
a 62 % crossover [12].
In order to more precisely estimate the potential size of
the problem I have performed a systematic review of the
literature, with the objective of determining whether
postnatal administration of pharmacological doses of
steroids, to ventilated preterm infants, for prevention or
treatment of bronchopulmonary dysplasia, is associated
with an increase in neuro-developmental impairment;
and of assessing the size of the effect.
Methods
In order for a trial to be included in this review it had to
be a report of a randomized controlled trial of glucocor-
ticoids given for the treatment or prevention of bron-
chopulmonary dysplasia. The study subjects had to be
premature infants, less than 32 weeks gestation. The out-
come measure of interest which was required was long
term neuro-developmental outcome at 1 year of age or
later.
A literature search was performed in February 2000 and
last updated on September 25th 2000. The medline data-
base was searched using the Pubmed search engine. The
search strategy included steroid* or glucocorticoid* and
bronchopulmonary dysplasia or chronic lung disease
and was limited to humans, newborn infants, and rand-
omized controlled trials. In addition I examined the ref-
erences of the latest edition of the Cochrane reviews on
postnatal steroid use, and other review articles, and
searched my personal data files using a similar search
strategy. During the preparation of this manuscript a
further publication appeared [13]. One of the reviewers
of the first version of this manuscript also pointed out 2
further publications, on which had not been found by my
first search [14] and a second, which was a letter in the
correspondence column of a journal, which included rel-
evant information [15]. I also searched the controlled
clinical trials register of the Cochrane database of con-
trolled clinical trials. After obtaining the initial results of
the search the abstracts of the articles or the entire article
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were reported.
Estimates of relative risk and risk difference were calcu-
lated using Metaview version 4.1, and 95% confidence in-
tervals were used. A fixed effect model was assumed. The
trials were subdivided into those that reported that there
was no contamination of the original randomization by
later treatment of controls with steroids, those with less
than 30% contamination, those with more than 30%
contamination and those with no clear report of the fre-
quency of treatment of controls with steroids. The stud-
ies with 0 to 30% contamination were separated
according to a pre-planned analysis and used to develop
estimates of risk.
Characteristics of the studies
Eight reports of randomized controlled trials, which in-
cluded some report of long-term neuro-developmental
outcomes, were obtained. Yeh et al investigated a 28 day
course of steroids, starting on day 1 in ventilated infants
less than 2000 g birth weight [16]. The initial sample size
was 262 infants, and both the randomization and the in-
tervention were masked. 83 infants died during initial
hospitalization, and 15 afterward, leaving a potential of
164 survivors to be followed, of these 22 were lost to fol-
low up in a further 9 follow up studies were not complet-
ed. This left a total of 133 infants for whom follow up data
are presented. Eight of the 70 control infants received
open label steroids after the study period (11.4%); five of
the 63 dexamethasone treated infants had further ster-
oids after the study period. At approximately 24 months
corrected age 81% of the surviving infants, n=133, had a
neuro-developmental examination including analysis of
motor disability and application of the Bayley scales of
infants development. In this study, steroid use was asso-
ciated with a 41% rate of significant handicap (severe
neurologic deficit or Bayley PDI and/or MDI less than
70) among 63 dexamethasone treated infants, compared
to a 31% rate among the 70 controls [17]. Follow up as-
sessment was masked to treatment group.
O'Shea et al studied a 42 day tapering course of steroids
in 118 very low birth weight infants (<1501 g birth
weight) who were ventilator dependent at 15 to 25 days
and requiring more than 30% O2. The method of rand-
omization is not clear from the study reports but the
medication administration was masked, no crossover of
study participants was allowed. Follow up of 93 of the 95
surviving infants was performed at one year corrected
age, using the Bayley scales, Vineland adaptive behav-
iour scales and a neuro-developmental examination.
This study showed that cerebral palsy frequency was 12/
48 steroid treated and 3/45 controls; the rate of neuro-
developmental impairment (cerebral palsy or Bayley
MDI <68 or blindness) was 16 out of 50 dexamethasone
treated infants and 8 out of 45 controls [10]. Outcome as-
sessment was masked.
Shinwell's data [13], are from follow up of 159 of the in-
fants enrolled in a multicentre trial in Israel [18]. This
study investigated 248 ventilated infants weighing less
than 2000 g, starting before 12 hours of life, 3 days of
dexamethasone or placebo were given. Both group allo-
cation and medication administration appear to have
been masked. Thirty of 116 controls (25.8%) received
open label steroids after the study, 26 of the 79 survivors
in this group (33%). 58 infants died during hospitaliza-
tion and 5 after discharge, 31 infants did not have ade-
quate data from follow up, which was performed at 24 to
71 months corrected age. There was therefore a total of
159 infants, 83.6% of the survivors, for whom adequate
data were available. The study demonstrated that 39 of
80 dexamethasone treated infants and 12 of 79 controls
had cerebral palsy, and also that only 36 of 80 dexame-
thasone treated infants had normal development com-
pared to 56 of 79 control babies. Not all of these infants
had formal developmental scoring, however, I have as-
sumed that infants referred to as "severely abnormal de-
velopment" were neuro-developmentally impaired by
my definition. Follow up examination was masked.
The fourth study to satisfy the criteria was the 1989 re-
port of the trial of Cummings et al [19]. In this study 36
infants of less than 1251 g birth weight who were ventila-
tor and oxygen dependent at 2 weeks of age were rand-
omized to either 42 days, or 18 days of steroids or to
control. Randomization and drug administration were
both masked; no crossover is mentioned in the report of
the study. Follow up assessment was performed at 15
months of age of all of the 23 surviving infants. Nine of
the 18 steroid treated infants who were followed up were
"normal" (normal neurological examination and Bayley
index >83) and 2 out of 5 controls. This study reported
that 5 out of 18 steroid treated and 2 of the five survivors
in the control group had either cerebral palsy or severe
truncal hypotonia. These results have been entered into
the meta-analysis as if all had cerebral palsy.
The collaborative dexamethasone trial group studied
282 very low birth weight infants, of whom 62 infants
died. The randomization schedule and the treatment
with steroids were both masked. There were 11 infants
not followed up to leave a total of 209 for whom there
was follow up information. Although rescue treatment
with steroids was supposed to be reserved for "life
threatening deterioration" this study reported a 43%
contamination rate of treatment of the whole control
group with steroids [11], being 40.4% of the surviving,
followed up controls. This European multicentre trial re-
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infants developed cerebral palsy, as assessed at a three
year follow up, and that 38/100 steroid treated and 41/
109 control infants were recognized as being disabled at
that time, most of whom probably fit my definition for
neuro-developmental impairment. It must be stated that
follow up methodology varied among the participating
centers, and it is not clear if it was masked.
In 1974 Fitzhardinge et al [14] published neuro-develop-
mental follow up data from 24 survivors of a study which
was not initially designed to investigate prevention of
bronchopulmonary dysplasia, and therefore was not dis-
covered by my first literature search which included that
search term. However, it is a report of follow up data
from a randomized controlled study [20], in preterm in-
fants. The infants in that study received 2 doses of 12.5
mg/kg of hydrocortisone 12 hours apart, the mean gesta-
tional age was about 32 weeks in both groups of infants,
therefore did not fit my original criteria for entry into the
systematic review, I have therefore performed the meta-
analysis both with and without the Fitzhardinge study,
and there is no major difference in the results, the graphs
include her study, in which there appears to have been no
contamination of the randomization schedule by treat-
ment of the controls with steroids. In this study steroid
treatment was associated with a substantial increase in
intraventricular hemorrhage, a decrease in scores on the
Griffiths scales of motor development from 104 to 93,
and a possible increase in gross neurological abnormali-
ties. There are probably 3 steroid and 1 control infant
with significant motor abnormalities at follow up who
could be defined as having CP, but one of the steroid
treated infants was not actually seen at 12 months. The
numbers of infants who have a developmental quotient
more than 2 SD below the mean is not given. I have
therefore added the infants with motor dysfunction to
the meta-analysis, but I have assumed that there were no
other infants with serious developmental delay, and
therefore, I have added the same numbers to the neuro-
developmental disability figures also.
The results from Subhedar's study have appeared in a
letter to the British Medical Journal. This study was orig-
inally a controlled trial of both dexamethasone and nitric
oxide inhalation, or both, in a factorial design, which in-
cluded 42 infants. Infants were enrolled at 96 hours of
age if they satisfied criteria for a high risk of bronchopul-
monary dysplasia. 22 infants survived, of whom 21 had
follow up examinations performed at 30 months correct-
ed age. Cerebral palsy rates were not different between
groups, nor were rates of significant developmental de-
lay or severe disability. No details of methodology were
included in this letter.
The final study has only been reported as an abstract [21]
and reports cerebral palsy rates (age of assessment un-
clear) of 4/9 steroid treated vs 2/8 control infants from
an original study with 10 infants in each group. No data
on other developmental outcomes were presented. I have
therefore also assumed a total rate of neuro-develop-
Figure 1
Meta-analysis of the effects of postnatal steroids on death. Studies are displayed in order of the degree of known con-
tamination of the randomization, Fitzhardinge and O'Shea known to have no contamination, Yeh, Shinwell, and Jones with pro-
gressively increasing degrees of contamination, and Cummings, Subhedar and Vincer unknown.
BMC Pediatrics (2001) 1:1 http://www.biomedcentral.com/1471-2431/1/1mental impairment of 4/9 and 2/8 followed up infants
respectively.
I recognize that the definition of impairment in each of
the studies has varied [10,17,19], nevertheless the pro-
portions of babies adversely affected is broadly compara-
ble, and there are some similarities in outcome
groupings. For the meta-analysis I have tried as far as
possible to apply a definition of neuro-developmental
impairment which includes all infants who have an ab-
normality which appears likely to affect day to day func-
tion, this includes a developmental quotient more than 2
standard deviations below the normal mean, a diagnosis
of cerebral palsy, and blindness. I recognize that some
infants with CP are not severely impaired, and that some
infants who do not fall into these groups may actually be
severely impaired, but given the limitations of the avail-
able data I think this is the optimal approach to deter-
mining the incidence of adverse neurological outcomes
that would be of interest to families.
Results of the analysis
The eight studies together randomized 1052 infants, 292
of whom are known to have died, the relative risk of
death is not statistically significant in any of the studies,
and there is no apparent effect of the extent of contami-
nation on mortality (Figure 1). For 679 of the surviving
infants some follow up data are available.
These studies demonstrate a relative risk for neuro-de-
velopmental impairment among all randomized infants
of 1.26 (95% CI 1.01, 1.58), which is within the confidence
intervals of each of the included studies (Figure 2). The
relative risk for neuro-developmental impairment
among surviving, followed up, infants overall is 1.34
(95% CI 1.09, 1.64). In those 4 studies with less than 30%
contamination the RR is 1.66 (95% CI 1.26, 2.19, figure
3). When only these studies, with less than 30% contam-
ination are included, the risk difference for neuro-devel-
opmental impairment among all randomized infants is
0.09, for a number needed to harm of 11. That is, for eve-
ry eleven patients eligible for steroid treatment, eight will
survive regardless of whether or not steroids are given, if
treated with steroids there will be 1 more surviving infant
with neuro-developmental impairment.
The relative risk for the development of cerebral palsy is
1.92 with steroids compared to control among all rand-
omized infants, (95% confidence intervals 1.41 to 2.61).
There appears to be a trend in the size of the apparent ef-
fect, which decreases as the degree of contamination in-
creases (figure 4). The relative risk for cerebral palsy
among surviving, followed up, infants in all the studies is
2.02 (95% CI 1.51, 2.71 figure 5) In those studies with less
than 30% contamination the relative risk for cerebral
palsy is 2.89 (95% CI 1.96, 4.27), the incidence of cere-
bral palsy being 78/203 (38%) in surviving, followed up,
treated infants and 28/206 (14%) in surviving controls, a
risk difference of 0.25. The risk difference among all ran-
domized infants in the studies with less than 30% con-
tamination is 0.14, which gives a number needed to harm
of 7. In other words for every 7 patients eligible for ster-
Figure 2
Meta-analysis of the effects of postnatal steroids on neurodevelopmental impairment, among all randomized
infants. Studies are displayed in order of the degree of known contamination of the randomization, Fitzhardinge and O'Shea
known to have no contamination, Yeh, Shinwell, and Jones with progressively increasing degrees of contamination, and Cum-
mings, Subhedar and Vincer unknown.
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ment, if administered steroids one more of the surviving
infants will develop cerebral palsy.
Discussion
The analysis herein is limited by the relatively small
number of infants who have been adequately assessed in
comparison to the huge numbers of children that have
been enrolled in more than 40 prospective trials. Fur-
thermore, the unwillingness of the neonatal community
to avoid giving control group infants glucocorticoids has
substantially impeded the ability to obtain useful follow
up information. The contamination of these results by
crossed over infants would tend to reduce any difference
between the groups, and thus probably reduces the ap-
parent size of the adverse effects that steroids have on
the developing brain. The figures, which show a progres-
sive reduction in the size of the apparent effect on cere-
bral palsy frequency as the extent of contamination
increases supports this contention. I have in this analysis
lumped together several studies with widely differing
timing of steroids and dosage schedules. The relative ho-
mogeneity of the results suggests that potent pharmaco-
logical doses of steroids at any age and at any dose may
not be safe for the brain of the premature infant, even a
3 day course is apparently associated with severely ad-
verse outcomes [18]. The groups of studies included
herein do not show any beneficial effect on mortality, nor
is there any evidence from the individual studies of long
term pulmonary benefit.
It must be admitted that the methodology of the follow
up studies varied widely, and in particular that the crite-
ria for the diagnosis of cerebral palsy are often not stated
in the publications, despite this many of the studies had
blinded assessment of the infants, including the 3 largest
studies of the group of 4 which had less than 30% con-
tamination, and therefore the relative effects are proba-
bly reliable, even if the severity of the consequent
disability need not necessarily be severe.
Recent data, from 1999, from the Vermont Oxford net-
work shows that among participating institutions (which
cover North America, Europe, the Middle East, the Far
East and Australasia) approximately 40% of extremely
low birth weight babies receive postnatal steroids. The
multi-centre Canadian NICU network provided me with
data for 1,085 extremely low birth weight infants who
survived to 28 days. By 28 days of life 38% of them had
received postnatal steroids, it is likely that still more in-
fants received steroids after 28 days. When we then esti-
mate the number of babies who have been injured by
steroids the over whelming size of this disaster becomes
apparent; of 360,000 infants born in Canada each year
approximately 1% are very low birth weight, with proba-
bly half of those weighing less than 1000 g, at least forty
% of these infants receive steroids, or 800 infants a year.
If the above calculations of "numbers needed to harm"
apply generally to this group of infants, then 70 extra in-
fants in Canada every year will have neuro-developmen-
tal impairment as a result of postnatal steroid treatment,
and 110 extra infants will have cerebral palsy. These esti-
Figure 3
Meta-analysis of the effects of postnatal steroids on neurodevelopmental impairment among surviving, fol-
lowed up, infants. Studies are displayed in order of the degree of known contamination of the randomization, Fitzhardinge
and O'Shea known to have no contamination, Yeh, Shinwell, and Jones with progressively increasing degrees of contamination,
and Cummings, Subhedar and Vincer unknown.
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mate the annual number of affected infants in the USA,
i.e. a birth rate of about 3.5 million per year, and a very
low birth weight incidence of 1.4% [22]. These huge
numbers are themselves probably an underestimate, as
they assume a threshold effect, with a proportion of in-
fants being affected to the extent of developing identifia-
ble neuro-developmental impairment, and the
remainder being unaffected. It seems much more likely
that impairment of brain growth is a consistent adverse
effect; certainly the impairment of somatic growth is very
consistent, and therefore the majority of infants receiv-
ing postnatal steroids are probably injured to a greater or
lesser extent.
This analysis strongly suggests that the single most effec-
tive intervention which could currently be introduced for
improving neuro-developmental outcomes of extremely
low birth weight infants would be to immediately aban-
don the use of postnatal steroids for chronic lung disease.
Abandoning all use of postnatal steroids for this indica-
tion would not increase mortality, prolong hospitalisa-
tion, or increase the numbers of infants receiving home
oxygen therapy. The only adverse effect would probably
be an increase in the duration of assisted ventilation, but
the financial costs of such an effect are easily dwarfed by
the reduced need for rehabilitation services, develop-
mental interventions, special schooling, and emotional
pain and suffering. Other interventions to reduce the du-
ration of assisted ventilation, including immediate sur-
factant administration, post-extubation nasal
ventilation, permissive hypercapnia and an attitude
which encourages weaning and extubation of even the ti-
niest of infants will probably mitigate this effect.
Is this effect surprising? Noble-Jamieson, in a small trial
in 1989, showed a substantial increase in ultrasound
brain abnormalities in dexamethasone treated infants
[23] a finding replicated by Shinwell's study [18]. One
large multi-centre trial was stopped because of increased
complications, which included periventricular leukoma-
lacia [24]. We have known for years that steroid use in
premature infants impairs growth, including head
growth [25], and that animal models show impaired
brain growth and development when exposed to steroids
[26]. Caution was urged 23 years ago [26] when antena-
tal steroids were first being used, which lead to extensive
evaluation of the neuro-developmental outcome of in-
fants after antenatal steroid administration and the doc-
umentation that adverse outcome was not increased. The
uncritical acceptance and use of postnatal steroids by the
majority of neonatologists, without any similar adequate
evaluation, is yet another object lesson in the need for
constant vigilance and scepticism.
The short term benefits of steroids: improved gas ex-
change, decreased ventilator requirements, and more
rapid extubation leading to shortened ventilator dura-
tion, are accompanied by an increase in many complica-
tions, including gastro-intestinal haemorrhage and
perforation, periventricular leukomalacia, hyperglycae-
Figure 4
Meta-analysis of the effects of postnatal steroids on cerebral palsy, among all randomized infants. Studies are dis-
played in order of the degree of known contamination of the randomization, Fitzhardinge and O'Shea known to have no con-
tamination, Yeh, Shinwell, and Jones with progressively increasing degrees of contamination, and Cummings, Subhedar and
Vincer unknown.
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long term adverse consequences do not seem to be asso-
ciated with any proven long term benefit.
It could be hypothesized that there may be a much lower
dose and shorter course of steroids which has some ben-
eficial effects on lung injury without adverse effects on
brain growth, however, such a dose regime has not been
defined, and searching for such a regime must only take
place within the context of adequately powered prospec-
tive randomized controlled trials which have neuro-de-
velopmental outcome as the primary outcome variable.
It may be that the use of less potent steroids, in doses de-
signed to mimic stress cortisol levels, may have a role to
play [27], such doses of steroids exert largely genomic ef-
fects, with a markedly different side effect profile, but the
same restrictions must be applied to studies investigat-
ing these high "physiologic" doses.
There have been calls for a further multicentre rand-
omized controlled trial to try and finally answer the
question of the risk benefit ratio of steroids. There are al-
ready some 42 randomized controlled trials in the litera-
ture, and despite that there is no clear long term benefit
from systemic pharmacologic doses of steroids. If infants
are not more likely to survive then I believe that few par-
ents will be willing to face the increased risk of neurolog-
ical damage. It seems to me to be highly unlikely that a
further trial will finally discover a benefit of sufficient
magnitude to outweigh the hazards which are presented
in this paper.
The introduction of some technologies and treatments
specific to the newborn, such as surfactant and to some
extent nitric oxide, have been models of the scientific
practice of  medicine with large, adequately powered,
prospective randomized controlled trials being per-
formed in sufficient numbers prior to the widespread use
of the treatments. These advances have been proven effi-
cacious, with clinically important endpoints, endpoints
in which parents and babies are interested, being clearly
improved by the treatments (survival, reducing the need
for ECMO), and adequate evaluation of long-term out-
comes having been undertaken. In contrast the uncritical
application of many treatments, of dubious efficacy and
uncertain long-term effects, continues. This is particu-
larly true to the extrapolation of data from adults or off
label use of medications that have never been investigat-
ed for newborns.
The one common thread in all of the neonatal disasters
outlined above is the uncritical introduction of therapies
without adequate evaluation. Future and continuing im-
provements in neonatal outcomes and avoidance of fu-
ture disasters will only occur if we make a concerted
effort to improve the reliability, applicability and useful-
ness of the evidence which is available, to propagate that
evidence and practice according to it.
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